AbbVie: Small Cell Lung Carcinoma trials

The registry lists 22 Small Cell Lung Carcinoma studies with AbbVie as lead sponsor. 3 are open to participants now and 8 have results posted.

Phase 1 14Phase 2 8Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerRecruitingNCT07365241Phase 3
• Expanded Access to ABBV-706AvailableNCT07310277
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerRecruitingNCT07155174Phase 2
• Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)CompletedNCT03061812Phase 3Results posted
• A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)TerminatedNCT03033511Phase 3Results posted
• A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerTerminatedNCT03026166Phase 1/2Results posted
• Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung CancerCompletedNCT02674568Phase 2Results posted
• Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung CancerCompletedNCT02289690Phase 1/2Results posted
• Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung CancerCompletedNCT01901653Phase 1/2Results posted
• A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung CancerTerminatedNCT01237678Phase 1/2Results posted
• Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung CancerCompletedNCT00065429Phase 1/2Results posted
• Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid TumorsActive, not recruitingNCT05599984Phase 1
• A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung CancerCompletedNCT03639194Phase 1
• A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid TumorsCompletedNCT03595059Phase 1
• Expanded Access to Rovalpituzumab TesirineNo longer availableNCT03503890
• Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung CancerWithdrawnNCT03334487Phase 3
• A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung CancerCompletedNCT03086239Phase 1
• A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung CancerCompletedNCT02874664Phase 1
• A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT02819999Phase 1
• SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine CarcinomaTerminatedNCT02500914Phase 1
• A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerCompletedNCT02391480Phase 1
• A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological MalignanciesCompletedNCT00445198Phase 1/2